Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Aug;10(8):4686-4688.
doi: 10.21037/jtd.2018.07.98.

Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore

Brian Cohen  1 , M Blair Marshall  1
Affiliations
Editorial

Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore

Brian Cohen et al. J Thorac Dis. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Forde PM, et al. N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658848 Free PMC article. Clinical Trial.

References

    1. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 2018;378:1976-86. 10.1056/NEJMoa1716078 - DOI - PMC - PubMed
    1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81. 10.1016/S0065-2776(06)90002-9 - DOI - PubMed
    1. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800. 10.1038/nm730 - DOI - PubMed
    1. Rounds A, Kolesar J. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer. Am J Health Syst Pharm 2015;72:1851-5. 10.2146/ajhp150235 - DOI - PubMed
    1. Keating GM. Nivolumab: a review in advanced squamous non-small cell lung cancer. Drugs 2015;75:1925-34. 10.1007/s40265-015-0492-9 - DOI - PubMed

LinkOut - more resources